Aquipta (Atogepant) for Migraine: Uses, Benefits, Risks and NHS Access

Aquipta has recently changed the treatment landscape for people who live with migraine in England. Whether you experience migraine attacks several times a week or a few times a month, understanding this medicine – how it works, who qualifies, and what to expect – can help you have a more informed conversation with your healthcare team. On this page, we break down everything you need to know.

Key Takeaways

• Aquipta (atogepant) is a prescription tablet used both to prevent migraine attacks and as an acute treatment of migraine with or without aura in adults.
• NICE approved atogepant for preventive use in 2024 and extended approval to acute treatment on the NHS in England on 10 June 2026.
• Aquipta is usually considered only after at least two different triptans plus NSAIDs and paracetamol have not worked or were not tolerated.
• As a gepant (CGRP receptor antagonist), Aquipta targets migraine-specific pathways, meaning it is less associated with medication overuse headache than many standard painkillers.
• Common side effects include nausea, tiredness and decreased appetite; seek urgent medical help for symptoms suggestive of acute infection, liver problems or severe allergic reaction.

What is Aquipta and who is it for?

Aquipta is the brand name for a prescription medicine that contains the active substance atogepant. It is designed specifically for adults with migraine, with or without aura, and is not a general painkiller.

Aquipta is licensed in the UK and EU for two uses:

• Acute treatment of migraine attacks in adults.
• Prevention (prophylaxis) in adults who have at least 4 migraine days per month.

Aquipta was authorized for use in the EU on 11 August 2023 by the European Medicines Agency, classified under the therapeutic area “Migraine Disorders” with ATC code N02CD07. It is not used to treat other conditions such as tension-type headache or cluster headache, and it is not currently licensed for children or teenagers.

A typical migraine attack involves intense throbbing pain – often on one side of the head – alongside feeling sick, sensitivity to light and sound, and sometimes aura (visual or sensory disturbances that should not last for longer than one hour). Migraine attacks usually last between 4 hours and 3 days, and some people face them several times a week. Understanding these symptoms is important because it helps determine whether Aquipta might be relevant. Decisions about prescriptions are made by a specialist or GP based on migraine frequency, severity, impact on daily life and response to other medicines.

How Aquipta (atogepant) works

This section gives a straightforward explanation of the medicine’s action without heavy jargon.

Aquipta is part of the gepants class of migraine medications – sometimes referred to by synonyms such as “CGRP receptor antagonists.” CGRP is a protein linked to migraine pain and inflammation; during an attack, CGRP is released and triggers a cascade of blood vessel changes and pain signalling in the brain.

Aquipta targets and blocks the CGRP receptor to prevent migraine symptoms. It also has weaker activity at the amylin-1 receptor. By interrupting these pathways, it can reduce the throbbing pain, nausea and sensitivity that define a migraine attack.

The distinction between its two uses matters:

• Preventive effect: taken regularly to reduce how often and how severely attacks occur over time.
• Acute effect: taken when a migraine attack starts – with an acute accent on early dosing – to shorten the attack and ease symptoms.

Because Aquipta works on migraine-specific pathways rather than being a general painkiller, it is less associated with medication overuse headache than frequent use of triptans, opioids or combination painkillers. That said, Aquipta does not cure migraine and does not work for every person. Migraine treatment may require trying multiple options, and Aquipta is one angle among other acute and preventive strategies, including lifestyle measures and cognitive behavioural therapy.

NICE approval and NHS access in England

NICE (the National Institute for Health and Care Excellence) issues guidance on which medicines the NHS in England can offer. Its recommendations carry significant weight for GPs and specialists alike.

Atogepant was first recommended by NICE as a preventive treatment for migraine in 2024. Then, on 10 June 2026, NICE issued new guidance approving atogepant for acute treatment of migraine on the NHS in England, as reported by The Migraine Trust. Atogepant is approved for acute migraine treatment in England and is also approved in the European Union for migraine treatment.

The main eligibility criteria for acute use are:

• Adults with migraine with or without aura.
• Who have tried at least 2 different triptans, plus NSAIDs and paracetamol.
• Where those earlier options were ineffective, not tolerated or contraindicated.

Local Integrated Care Boards (ICBs) decide how people can access Aquipta. In some areas, GPs may be able to prescribe it in primary care; in others, patients need a refer to a neurologist or specialist headache clinic. The Migraine Trust and other advocates have raised concerns that access to CGRP treatments can vary widely across England, meaning some people face longer waits and are unable to get treatment promptly.

Practical steps: speak to your GP, keep a detailed migraine diary, and check your local ICB’s page or headache clinic referral pathways for the latest information on access.

Using Aquipta: doses, timing and what to expect

Exact dose and schedule must follow prescribing information and a clinician’s advice. The examples below are for general orientation only.

Aquipta is available in tablet form and taken by mouth with water, with or without food. It can be used in two ways:

For preventive use, Aquipta can reduce migraine days from 8 to 3–4 monthly, reviewed over around 12 weeks. NICE recommends reviewing Aquipta’s effectiveness after 12 weeks of treatment. For acute use, some patients notice improvement within two hours of dosing.

Keep a migraine diary tracking the number of migraine days, severity of pain, need for other acute medicines, and impact on work or daily activities. Do not exceed the maximum daily dose, and if a dose is missed, take it when remembered unless it is almost time for the next dose – never double up without medical advice.

Effectiveness and safety: what the studies show

Aquipta has been reviewed in several clinical studies for both prevention and acute treatment.

Preventive findings: adults with at least 4 migraine days per month who took atogepant daily showed fewer migraine days compared with placebo. Aquipta can reduce migraine days from 8 to 3–4 per month. A higher proportion of people also achieved at least a 50% reduction in monthly migraine days. These sources of evidence included the PROGRESS trial published in the NEJM.

Acute findings: Aquipta is effective for treating acute migraine attacks. Around 24% of patients were pain-free 2 hours after taking Aquipta, compared with about 13% on placebo. Studies showed that people were able to return more quickly to normal activities, with meaningful relief from their most bothersome symptom.

Common side effects (generally mild to moderate):

• Nausea
• Tiredness or fatigue
• Decreased appetite
• Constipation and mild stomach discomfort

Most common side effects of Aquipta include nausea and constipation, but side effects of Aquipta are generally mild to moderate. Regulatory bodies such as the EMA and MHRA judged that benefits outweigh these risks when used as recommended.

Serious but less common risks requiring urgent care:

• Signs of acute infection – high fever, rash, feeling very unwell (to distinguish from routine migraine)
• Possible liver injury (dark urine, yellowing of skin or eyes, severe upper stomach pain)
• Severe hypersensitivity reactions can occur with Aquipta (sudden onset swelling of face, lips, tongue, difficulty breathing)

Aquipta is under additional safety monitoring in the EU, so patients may be asked to report side effects via national yellow card or pharmacovigilance schemes. Weight changes and decreased appetite have also been noted in a small number of people.

Comparing Aquipta with other migraine treatments

Aquipta is usually tried after standard migraine treatments. Here is how it compares from a variety of angles:

• vs. Triptans: triptans work on serotonin receptors and narrow blood vessels. Some people cannot take them due to heart or circulation conditions, or they face strong effects. Aquipta offers a different mode of action where triptans have failed.
• vs. General painkillers: paracetamol and NSAIDs can manage mild attacks but often fall short for severe migraine. Frequent use increases the risk of medication overuse headache; gepants appear to carry a lower risk.
• vs. Injectable CGRP monoclonal antibodies (such as erenumab or fremanezumab): these are given monthly or quarterly by injection. Aquipta is an oral tablet, which may suit people who prefer tablets or who cannot access injectables through local pathways.

Some people still need a combination: Aquipta for prevention, a triptan or NSAID for occasional acute use, plus lifestyle measures like regular sleep, hydration and trigger management. Menstrual migraines are often longer and more severe, so treatment choice may involve specialist input. Most people find their migraine attacks improve with age, but finding the right combination matters now.

Who should avoid Aquipta and when to seek urgent help

Aquipta is not suitable for everyone – safety comes first.

Extra caution or avoidance needed if you have:

• Severe liver disease or a history of significant liver problems
• Pregnancy or breastfeeding – Aquipta is not recommended during pregnancy due to limited safety data
• Medicines that strongly affect liver enzymes (certain antifungals, antivirals or anti-seizure medicines are involved)
• A history of serious allergic reaction to atogepant or any ingredient

Seek urgent medical advice if:

• Migraine attacks suddenly change in pattern, become much more severe, or come with new neurological symptoms (weakness, confusion, speech difficulty)
• You develop persistent high fever, stiff neck or rash – this might point to an acute infection or meningitis rather than a migraine
• You notice dark urine, yellowing skin or a severe allergic reaction with swelling of the face

Call 999 if there are signs of stroke, a sudden severe “thunderclap” headache, collapse, seizures or trouble breathing. Do not drive to A&E during a severe neurological emergency. Keep an up-to-date list of all medicines and supplements you use and share it at every appointment so the prescriber can check for interactions.

FAQs about Aquipta for migraine

Is Aquipta used for both prevention and acute treatment of migraine?

Yes. Aquipta is licensed for acute treatment of migraine attacks with or without aura in adults and for preventive treatment in adults who have at least 4 migraine days per month. How it is prescribed – daily preventive, as-needed acute, or both – depends on individual needs and local NHS policies. The meaning of each approach differs: prevention aims to reduce attack frequency, while acute use targets a single episode.

Can I take Aquipta at the same time as my usual triptan?

Some people may be advised to use Aquipta alongside a triptan or NSAID, but this must be decided by a clinician who has reviewed all your medicines and health conditions. Never combine treatments on your own – doing so without healthcare guidance risks interactions and medication overuse.

How long does it take for Aquipta to start working?

For acute treatment, around 24% of patients were pain-free 2 hours after taking atogepant, though results vary. For prevention, benefits are usually assessed after several weeks to 3 months. NICE recommends reviewing effectiveness after 12 weeks, using a migraine diary to track changes in the number of attacks and migraine days.

Is Aquipta suitable if I get menstrual migraine?

Aquipta can be considered for adults whose migraine attacks are linked to their menstrual cycle, especially if attacks are frequent or severe. Treatment choice depends on overall migraine pattern, other conditions, and whether you are trying to conceive, pregnant or breastfeeding – specialist advice is recommended.

Will Aquipta affect my risk of infections or acute illness?

Aquipta does not suppress the immune system the way some other medicines do, and it is not known to increase the overall risk of acute infection. Still, if you develop high fever, rash, confusion, stiff neck or start feeling suddenly very unwell at any times, seek prompt medical review to rule out serious causes that may mimic or complicate a migraine attack. Support from your GP or NHS 111 can help you decide the right next step.